|
NPPA fixes retail price of 45 formulations
|
|
Our Bureau, New Delhi
August 26 , 2022
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 45 formulations under the Drugs (Prices Control) Order, 2013, based on the decision of the 100th Authority meeting held this month.
The list of drugs which has prices fixed include various strengths of anti-diabetes drug sitagliptin combination, which went off patent recently and has seen several generic players jumping in to the market.
Almost 25 out of the 45 drugs in the list are sitagliptin combinations, marketed by players including Torrent Pharmaceuticals, Micro Labs, Primus Remedies, Alembic Pharmaceuticals, Intas Pharmaceuticals, Cipla Ltd, and J B Chemicals and Pharmaceuticals.
Two formulations with anti-diabetes drug linagliptin, for which the patent is scheduled to expire in 2025 according to reports, are also in the list, to be marketed by Eris Lifesciences Ltd.
The drug formulations for which retail prices were fixed include cyclosporine eye drop marketed by Intas Pharmaceuticals, combination of omeprazole (GR) and domperidone (SR) capsules from Cadila Pharmaceuticals, pantaprazole dual release gastro resistant tablets marketed by Hetero Healthcare, gastro-resistant rs omeprazole and domperidone sustained release capsule from Mankind Prime Labs, amlodipine and atenolol tablets from Softdeal Pharmaceuticals, etamsylate and tranexamic acid tablets from Torrent Pharmaceuticals, combination of paracetamol, phenylephrine hydrochloride, caffiene and diphenhydramine hydrochloride tablets from German Remedies among others.
The manufacturer of these formulations may add Goods and Services Tax (GST) to the fixed retail price and only if they have paid actually or it is payable to the government.
Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
In case the retail price of any of these formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer or marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|